Kamada

Update in progress

KMDA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Kamada Ltd. develops, manufactures and distributes plasma‑derived protein therapeutics and related biopharmaceuticals. Its products include KAMRAB/KEDRAB for rabies prophylaxis; CYTOGAM for CMV prophylaxis in transplant patients; VARIZIG for varicella exposure; WINRHO SDF for ITP; HEPAGAM B for hepatitis B prevention; GLASSIA for alpha-1 antitrypsin deficiency; RUCONEST for angioedema; IVIG and BEVACIZUMAB KAMADA, among others. Based in Rehovot, Israel, founded in 1990.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.28; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive